Clinical trials: RhA - Rheumatoid Arthritis
Rheumatoid Arthritis
A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to…
- Trial name
- NCT00650767
- Testing
- ARRY-438162, MEK inhibitor; oral
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 201 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Osteoarthritis, Rheumatoid Arthritis
Exceed ABT Acetabular Cup Cementless System
A Post-market Clinical Follow-up Study to provide safety, performance and clinical benefits data on the Exceed ABT acetabular cup (implants and instruments) when used in combination with ceramic liners or polyethylene…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Correction of Functional Deformity
- Trial name
- NCT04255394
- Volunteers
- 677 people
- Sponsor
- Zimmer Biomet
Arthritis, Rheumatoid
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study).
- Trial name
- NCT00281294
- Testing
- Fontolizumab
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- PDL BioPharma, Inc.
Rheumatoid Arthritis
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis
This retrospective, observational, multi-center study will evaluate the use of biological agents (e.g. RoActemra/Actemra [tocilizumab]) in monotherapy in patients with rheumatoid arthritis.
- Trial name
- NCT01834807
- Where
- 14 sites in Belgium
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Healthy, Rheumatoid Arthritis
MAD Study of IA-14069
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with…
- Trial name
- NCT05533372
- Testing
- IA-14069, Methotrexate
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ILAb Co., Ltd.
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
This study (contRAst 3 [202018: NCT04134728]) is a Phase 3, randomized, multicenter, double-blind study to assess the safety and efficacy of GSK3196165 in combination with conventional (cs) DMARD[s]) or the treatment of adult…
- Trial name
- contRAst 3 (NCT04134728)
- Testing
- GSK3196165 (Otilimab), Sarilumab, csDMARDs
- Where
- 131 sites in United States, Argentina and 13 more
- Volunteers
- 550 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants…
- Trial name
- NCT01941095
- Testing
- Azathioprine, Chloroquine, Hydroxychloroquine
- Where
- 10 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT03139136
- Testing
- MBS2320
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 121 people
- Sponsor
- Modern Biosciences Ltd
Rheumatoid Arthritis
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
This was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD)…
- Trial name
- NCT00902486
- Testing
- INCB028050
- Where
- 49 sites in United States, Czechia
- Volunteers
- 127 people
- Sponsor
- Incyte Corporation
Osteoarthritis, Rheumatoid Arthritis
NexGen TM Tibia Clinical Outcomes Study
The objective of this study is to evaluate clinical performance for the commercially available NexGen TM Monoblock Tibia and NexGen TM Modular Tibia used in primary cementless tibia total knee arthroplasty.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis
- Trial name
- NCT03272373
- Testing
- NexGen TM Monoblock Tibia, NexGen TM Modular Tibia
- Where
- 7 sites in United States
- Volunteers
- 160 people
- Sponsor
- Zimmer Biomet
Knee Pain Chronic, Rheumatoid Arthritis
Cemented vs Cementless Persona Keel RCT
The main objective of this study is to evaluate the safety, performance, and clinical benefits of the Persona Keel cementless and cemented knee.
- Conditions
- Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis
- Trial name
- NCT05630053
- Testing
- Cementless Persona Knee System, Cemented Persona Knee System
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who…
- Trial name
- NCT00048581
- Testing
- Abatacept
- Where
- 42 sites in United States
- Volunteers
- 738 people
- Sponsor
- Bristol-Myers Squibb
Moderately to Severely Active Rheumatoid Arthritis
A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis
This is a Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
- Trial name
- NCT06738719
- Testing
- CT-P13 SC Auto-Injector
- Where
- Poland
- Volunteers
- 192 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing
To demonstrate the efficacy of 80 mg adalimumab monthly dosing compared with placebo and demonstrate the non-inferiority of monthly dosing of 80 mg adalimumab compared with dosing of 40 mg adalimumab every other week.
- Trial name
- NCT00647270
- Testing
- adalimumab
- Where
- 86 sites in United States, Australia and 4 more
- Volunteers
- 420 people
- Sponsor
- Abbott
Arthritis, Rheumatoid
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
The primary objectives of this trial are (1) To show PK (Pharmacokinetic) similarity of BI 695500 to rituximab. (2)To establish statistical equivalence of efficacy of BI 695500 and rituximab, in patients with moderately to…
- Trial name
- NCT01682512
- Testing
- BI 695500, Rituxan®, MabThera®
- Where
- 110 sites in United States, Argentina and 15 more
- Volunteers
- 294 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
This six months non-interventional, observational, post-marketing, multi-center and local study will evaluate the differences in the use of corticosteroids between RA participants receiving TCZ or a TNF-inhibitor, in participants…
- Trial name
- NCT02679001
- Testing
- TNF inhibitor/TCZ
- Where
- 11 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
- Trial name
- NCT01626573
- Testing
- Itacitinib
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Incyte Corporation
Rheumatoid Arthritis
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment
This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use in a representative cohort of…
- Trial name
- CONIFER (NCT03112213)
- Testing
- Tocilizumab, NSAIDs
- Where
- 27 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with…
- Trial name
- FALLA (NCT01083160)
- Where
- 12 sites in Mexico
- Volunteers
- 82 people
- Sponsor
- Abbott
Rheumatoid Arthritis
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.
- Trial name
- NCT00152386
- Testing
- Certolizumab pegol (CDP870)
- Where
- 76 sites in United States, Argentina and 11 more
- Volunteers
- 950 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.